PRLD Earnings Report
Prelude Therapeutics Incorporated reported earnings of per PRLD share on Nov 16, 2026, falling short of analysts' expectations by
| Report Date | Nov 16, 2026 |
|---|---|
| Forecasted EPS | $ 0.01 |
| Last Year's EPS | -$ 0.32 |
| EPS YoY Change |
Prelude Therapeutics Incorporated reported earnings of per PRLD share on Nov 16, 2026, falling short of analysts' expectations by
| Report Date | Nov 16, 2026 |
|---|---|
| Forecasted EPS | $ 0.01 |
| Last Year's EPS | -$ 0.32 |
| EPS YoY Change |
Out of the last 31 earnings reporting periods, Prelude Therapeutics Incorporated beat analysts’ expectations 18 times and fell short of expectations 7 time(s). Prelude Therapeutics Incorporated reported earnings per share of in the last report falling to reach an estimated EPS of $ 0.01 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 16, 2026 | $ 0.01 | -$ 0.41 | - | |
| Aug 11, 2026 | -$ 0.20 | -$ 0.14 | -$ 0.42 | |
| May 12, 2026 | -$ 0.27 | -$ 0.13 | -$ 0.38 | |
| Mar 10, 2026 | -$ 0.33 | -$ 0.20 | -$ 0.43 | |
| Nov 12, 2025 | -$ 0.35 | -$ 0.26 | -$ 0.46 | |
| Aug 14, 2025 | -$ 0.45 | -$ 0.41 | -$ 0.42 | |
| May 6, 2025 | -$ 0.47 | -$ 0.42 | -$ 0.46 | |
| Mar 10, 2025 | -$ 0.48 | -$ 0.38 | -$ 0.45 | |
| Nov 6, 2024 | -$ 0.47 | -$ 0.43 | -$ 0.54 | |
| Aug 12, 2024 | -$ 0.43 | -$ 0.46 | -$ 0.58 | |
| May 7, 2024 | -$ 0.48 | -$ 0.42 | -$ 0.60 | |
| Feb 15, 2024 | -$ 0.49 | -$ 0.46 | -$ 0.63 | |
| Nov 1, 2023 | -$ 0.58 | -$ 0.45 | -$ 0.58 | |
| Aug 3, 2023 | -$ 0.63 | -$ 0.54 | -$ 0.63 | |
| May 8, 2023 | -$ 0.68 | -$ 0.58 | -$ 0.71 | |
| Mar 15, 2023 | -$ 0.63 | -$ 0.60 | -$ 0.66 | |
| Nov 14, 2022 | -$ 0.64 | -$ 0.63 | -$ 0.58 | |
| Aug 9, 2022 | -$ 0.61 | -$ 0.58 | -$ 0.47 | |
| May 10, 2022 | -$ 0.65 | -$ 0.63 | -$ 0.45 | |
| Mar 16, 2022 | -$ 0.68 | -$ 0.71 | -$ 5.25 |
Prelude Therapeutics Incorporated’s stock was trading at on Nov 15, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Aug 11, 2026 | -$ 0.14 | $ 4.83 | $ 5.73 | |
| May 12, 2026 | -$ 0.13 | $ 4.80 | $ 4.66 | |
| Mar 10, 2026 | -$ 0.20 | $ 3.09 | $ 3.81 | |
| Nov 12, 2025 | -$ 0.26 | $ 1.35 | $ 1.51 | |
| Aug 14, 2025 | -$ 0.41 | $ 0.907 | $ 0.87 | |
| May 6, 2025 | -$ 0.42 | $ 0.8216 | $ 0.7643 | |
| Mar 10, 2025 | -$ 0.38 | $ 0.736 | $ 0.661 | |
| Nov 6, 2024 | -$ 0.43 | $ 1.29 | $ 1.27 | |
| Aug 12, 2024 | -$ 0.46 | $ 5.10 | $ 6.20 | |
| May 7, 2024 | -$ 0.42 | $ 3.83 | $ 3.59 | |
| Feb 15, 2024 | -$ 0.46 | $ 3.38 | $ 4.63 | |
| Nov 1, 2023 | -$ 0.45 | $ 1.69 | $ 2.21 | |
| Aug 3, 2023 | -$ 0.54 | $ 3.75 | $ 3.67 | |
| May 8, 2023 | -$ 0.58 | $ 6.51 | $ 6.26 | |
| Mar 15, 2023 | -$ 0.60 | $ 6.01 | $ 6.56 | |
| Nov 14, 2022 | -$ 0.63 | $ 8.50 | $ 7.80 | |
| Aug 9, 2022 | -$ 0.58 | $ 6.55 | $ 7.97 | |
| May 10, 2022 | -$ 0.63 | $ 4.00 | $ 4.04 | |
| Mar 16, 2022 | -$ 0.71 | $ 7.15 | $ 8.36 | |
| Nov 12, 2021 | -$ 0.66 | $ 16.76 | $ 15.85 |
Prelude Therapeutics Incorporated released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Prelude Therapeutics Incorporated missed analysts’ expectations during the last earnings period by